# Compass Therapeutics

Compass Therapeutics is a Venture Capital based in Boston, United States.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** Boston, United States
- **Region:** North America
- **Address:** 80 Guest Street, Suite 601, Boston, MA 02135, United States
- **Founded:** 2014
- **Assets under management:** Undisclosed
- **Website:** compasstherapeutics.com

## Regulatory record

- **Reports private funds:** No

## About

Compass Therapeutics is a clinical-stage biopharmaceutical company founded in 2014 in Boston, Massachusetts. The company develops antibodies targeting biological pathways such as angiogenesis and immune system modulation. Formerly known as Kairos Biologics Foundation, Compass Therapeutics advances product candidates through clinical development as standalone and combination therapies.

## Sectors

- Biotechnology
- Oncology
- Immunotherapy

## Offices

- New York, NY, United States

## People

- Thomas J. Schuetz — Chief Executive Officer
- Barry Shin — Chief Financial Officer
- Arjun Prasad — Chief Commercial Officer
- Cynthia Sirard — Chief Medical Officer
- Bing Gong — Chief Scientific Officer
- James Boylan — Director
- Carl Gordon — Director

## Questions

### Who runs investment decisions at Compass Therapeutics?

Thomas J. Schuetz, MD, PhD, co-founder and CEO, leads strategy; the board includes venture investors from OrbiMed and Borealis. No dedicated CIO is listed (per firm website).

### What investment stages does Compass Therapeutics target?

Compass does not make external investments; it develops its own drug candidates from discovery through clinical trials (per firm website).

### Which sectors does Compass Therapeutics explicitly avoid?

Compass focuses exclusively on therapeutic antibodies for oncology and autoimmune diseases. It does not invest in medical devices, diagnostics, or non-therapeutic biotech (per firm pipeline description).

### How does Compass Therapeutics source proprietary deal flow?

Compass generates its own pipeline internally through its StitchMabs and common light chain platforms, not through external sourcing (per firm website).

### Does Compass Therapeutics participate in fund commitments or only direct deals?

Compass does not function as a capital allocator. It raises equity from venture investors and public markets to fund its own internal R&D programs (per firm structure).

### What is Compass Therapeutics's known posture on co-investments alongside external GPs?

Compass does not engage in co-investments. It is a single-entity drug developer, not a fund-of-funds or co-investment vehicle (per firm website).

## Related profiles

- [Filevine](https://altss.com/profile/filevine)
- [Eaton Vance](https://altss.com/profile/eaton-vance)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/compass-therapeutics

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology